ClinicalTrials.gg
CompletedNCT03596632Updated Dec 6, 2018

Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers

A Phase 1 interventional study of Fenebrutinib in Healthy Participants, sponsored by Hoffmann-La Roche. Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-06.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was Aug 2018, 8 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

The purpose of this study is to determine the excretion kinetics and mass balance of fenebrutinib in healthy male subjects.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects, between 18 and 60 years of age, inclusive
  • Within range 18 to 32 kg/m2, inclusive
  • In good health, determined by no findings from medical history, 12-lead (ECG), vital signs, and physical examination
  • For males who are sterile: agreement to use a condom with a fertile or pregnant female partner from Day -1 until 90 days following Study Completion; for males who are fertile: agreement to use a condom with spermicide with a fertile or pregnant female partner from Day -1 until 90 days following Study Completion

Exclusion criteria

Exclusion Criteria:

  • History or symptoms of any significant disease
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator
  • History of stomach or intestinal surgery or resection, except appendectomy, hernia repair, and cholecystectomy
  • History of , except for non-melanoma skin carcinoma with 3-year disease-free follow-up
  • Participation in any other study drug trial in which receipt of an investigational study drug occurred within 30 days or 5 half-lives, whichever is longer, prior to Day -1
  • Exposure to significant diagnostic or therapeutic radiation or current employment in a job requiring radiation exposure monitoring within 12 months prior to Day -1
  • Participation in a radiolabeled drug study in which exposures are known to the Investigator within 4 months prior to Day -1, or participation in a radiolabeled drug study in which exposures are not known to the Investigator within 6 months prior to Day -1. The total 12-month exposure from this study and a maximum of 2 other studies must be within the Code of Federal Regulations (CFR) recommended levels considered state (per 21 CFR 361.1), e.g. less than 5,000 mrem whole body annual exposure
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Single Oral Solution Dose

    Single 200-mg (approximately 100-µCi) oral solution dose of \[14C/12C\]-fenebrutinib under fasted conditions.

    Drug: Fenebrutinib

Interventions

  • 200-mg (100 µCi) oral solution 14C/12C\]-fenebrutinib

    Also known as: RO7010939

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Percentage of the Total Radioactive Dose Administered Excreted from Urine and Feces"; TimeFrame: "Day 1 to end of study (approximately 35 days post-dose)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any AE that can be fatal, life threatening, prolongs inpatient hospitalization, significant disability, congenital anamoly, is a significant medical event in the Investigator's judgment.

    Time frame: Screening to end of study (approximately 35 days post-dose)

Secondary outcomes

  1. Maximum Observed Concentration (Cmax) of Fenebrutinib and its Metabolites

    Time frame: Day 1 pre-dose to end of study (approximately 35 days post-dose)

  2. Time to Observed Maximum Concentration (Tmax) of Fenebrutinib and its Metabolites

    Time frame: Day 1 pre-dose to end of study (approximately 35 days post-dose)

  3. Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Fenebrutinib and its Metabolites

    Time frame: Day 1 pre-dose to end of study (approximately 35 days post-dose)

  4. Area under the Concentration-Time Curve Extrapolated to Infinity (AUC0-infinity) of Fenebrutinib and its Metabolites

    Time frame: Day 1 pre-dose to end of study (approximately 35 days post-dose)

  5. Cumulative Percent of Total Radioactivity Excreted in Urine Over the Sampling Interval (Total % Feu)

    Time frame: Day 1 pre-dose to end of study (approximately 35 days post-dose)

  6. Cumulative Percent of Total Radioactivity Excreted in Feces Over the Sampling Interval (Total % Fef)

    Time frame: Day 1 pre-dose to end of study (approximately 35 days post-dose)

  7. Number of Participants With Clinical Significant Changes in Vital Signs

    Vital signs incudes oral temperature, respiratory rate, supine blood pressure and pulse.

    Time frame: Screening up to Day 31

  8. Number of Participants With Clinical Significant Changes in Physical Examination Findings

    Physical examination will consist of an assessment of general appearance, skin, thorax/lungs, abdomen, lymph nodes, head, ears, eyes, nose, throat, neck (including thyroid); and cardiovascular, musculoskeletal, and neurological systems.

    Time frame: Day -1, 28

  9. Number of Participants With Clinical Significant Changes in Clinical Laboratory Results

    Laboratory analysis include chemistry panel, complete blood count and urinalysis.

    Time frame: Screnning, Day -1, 2, 4, 28

  10. Number of Participants With Clinical Significant Changes in Electrocardiograms (ECGs)

    Time frame: Screening, Day-1, 1 (Pre-dose; 1, 3 hours [h] post-dose), 28, 31

07

Study locations

1 site
  • Covance Clinical Research Unit, Inc
    Madison, Wisconsin 53704, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Aug 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2018
First posted
Jul 24, 2018
StartActual
Jul 27, 2018
Primary completionActual
Aug 23, 2018
CompletionActual
Aug 23, 2018
Last update
Dec 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03596632
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 24, 2018
Start date
Jul 27, 2018
Primary completion
Aug 23, 2018
Completion
Aug 23, 2018
Last update
Dec 6, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenebrutinib

Start the discussion